Lilly Reveals New Data for Olumiant (baricitinib) to Treat Rheumatoid Arthritis and Systemic Lupus Erythematosus #EULAR
Shots:
- Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg- qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study measured LDA as measured by SDAI ≤11- in DMARD-naïve patients and patients with an inadequate response to MTX from treatment initiation to 3yrs.
- The study found that among patients with an inadequate response to MTX- 52% of patients initially treated with Olumiant + MTX were in a state of SDAI LDA @24wks. and the rate is maintained @148wks. Lilly will also present an updated safety analysis of Olumiant in the treatment of RA utilizing data from 3-770 patients taking medicine for up to 8.4yrs.
- Additionally- Lilly will present analyses from an investigational trial evaluating Olumiant in patients with SLE at EULAR. Further- data from P-II JAHH study will be highlighted- which observed whether SLE patients experienced changes in their serum cytokine levels- following Olumiant (4mg)
Click here to read full press release/ article | Ref: Eli Lilly | Image: D&P Event
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com